Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

This is the cold season, and many people are down with runny nose, fever, cough, and tiredness. However, according to experts ...

Most major sections of the new animal drug application for Laverdia-CA1 have been deemed complete by the FDA, bringing the ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Shares of Tempus AI (TEM) are rising 5% in pre-market trading after surging 13% yesterday. The healthcare-focused AI stock ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

Members of the Leukemia and Lymphoma Society discussed the importance of educating others, fundraising and spreading ...

Tempus AI, Inc. (NASDAQ:TEM) stock is trading higher on Thursday after the company announced a collaboration with the ...